The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial.
Markus Hermann Moehler
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Other Remuneration - Pfizer
Peter C. Thuss-Patience
No relevant relationships to disclose
Hans-Joachim Schmoll
No relevant relationships to disclose
Susanna Hegewisch-Becker
No relevant relationships to disclose
Hansjochen Wilke
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Florian Weissinger
No relevant relationships to disclose
Frank Kullmann
No relevant relationships to disclose
Ludwig Fischer Von Weikersthal
No relevant relationships to disclose
Jens T. Siveke
No relevant relationships to disclose
Stephan Kanzler
No relevant relationships to disclose
Carl Christoph Schimanski
No relevant relationships to disclose
Melanie Otte
No relevant relationships to disclose
Lukas Schollenberger
No relevant relationships to disclose
Jochem Koenig
No relevant relationships to disclose
Peter Robert Galle
No relevant relationships to disclose